The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma. Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

The company reported revenue of $10.97 billion and earnings of $1.34 on a per-share and adjusted basis, compared to the consensus estimates of $11.01 billion and ...

Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management.

One cupcake won't kill you,' 'I'm going to get diabetes just looking at that,' 'That person doesn't look like they have ...

Argus analyst David Toung raised the firm’s price target on Abbott (ABT) to $150 from $145 and keeps a Buy rating on the shares. Abbott’s ...

Abbott Laboratories is a well-diversified health care company, with four distinct units: medical devices, diagnostics, nutrition and ...

The system – which already has a breakthrough device designation from the FDA – will take the form of a small patch-like device similar to Abbott's FreeStyle Libre 3 device (pictured above ...

Abbott has won an innovation award for Lingo, its first consumer biowearable over-the-counter device to empower people in improving overall health and wellness.

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...